Republican Congress To Shift Priorities, But Cancer May Get New Opportunities
In Brief: Ortho Biotec gives $1 Million To Fund Fatigue Initiative; Lippman, Pike Honored
NCI Won’t Recognize Wolmark Wile NSABP is Plaintiff In Suit
DCE Advisors Okay Contract Recompetitions For Epidemiology
Chemical Carcinogenesis
FDA Rile Changes Reporting Requirements for Adverse Events
Trending Stories
- Is it time to re-assess the practice and practicality of screening colonoscopy?
Modeling data, ACS guideline support greater use of noninvasive tests to ease system strain, help save lives - Michael Caputo appointed to President’s Cancer Panel
The cancer survivor and political operative says his appointment signals Trump’s interest in cancer, survivorship - The Galleri MCD vote: What FDA asked its advisors to ignore
- From “default dead” to living the future of cancer care
As founding CEO of GitLab, I went “founder mode” on my osteosarcoma - FDA advisory committee votes in favor of Galleri approval, but calls for removal of “early” detection claims
Clinical benefit will not be considered for approval, FDA says - The Directors: Two Gulf Coast cancer center directors on why NCI designation matters—and why they want it
Lucio Miele and Raghu Kalluri: Science and technology have changed what an aspiring cancer center must accomplish
